Clinical trial NCT03972813: Optimizing HPV Vaccine Introduction in Shanghai, China
Official title: Optimizing HPV Vaccine Introduction in Shanghai, China
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Vaccine Refusal
Keywords: HPV Vaccines
China
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Shanghai Municipal Center for Disease Control and Prevention
name: National Institute of Allergy and Infectious Diseases (NIAID)
First posted: 2019-06-04
Enrollment: 1021
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: In this educational intervention, there are three dimensions of variability: cancer messaging, communicability messaging, and age messaging. For cancer messaging there are two possibilities: one message focused more on cervical cancer, one message on cancer in general. For communicability, one message will have information on sexual transmission, a second on infectiousness in general, and a third will have no information about communicability. For age, one will mention that the vaccine is available for 9-45 year olds, the second will mention that and additionally recommend children 11 years old to receive the vaccine, and the third will recommend children 18 years old to receive the vaccine.
Primary purpose: PREVENTION

Brief summary: Within low, middle, and upper income countries, low vaccine coverage results from both obstacles to vaccine access and low confidence in vaccine programs. Thus, it is critical to determine how best to enhance trust in vaccines as increasing numbers of vaccines are recommended for use. Even though the context accompanying the initial roll-out of a vaccine can have a large impact on people's perceptions of the vaccine and the corresponding disease, it is not clear how to best introduce a vaccine to increase public confidence and enhance uptake. The US roll-out of the human papillomavirus (HPV) vaccine framed HPV as a sexually transmitted infection, which proved to be an impediment to efforts to increase vaccine uptake \>10 years after its introduction. This study will use an educational experiment, where parents of children will be exposed to information about the HPV vaccination in different ways. Parents will be introduced to the HPV vaccine through different scenarios with varying emphases (i.e., age at vaccination, types of transmission, type of cancer prevention). The aim will be to determine how the framing of the HPV vaccination across several dimensions affects short-term willingness to receive it.


Eligibility criteria: Inclusion Criteria:

* Parents of children 2-18 years old.

Exclusion Criteria:

* None

Primary outcomes:
measure: To Determine How the Framing of the HPV Vaccination Across Several Dimensions Affects Short-term Willingness to Receive it
timeFrame: same day as intervention
Secondary outcomes:
measure: To Determine How the Framing of the HPV Vaccination Across Several Dimensions Affects Sustained Willingness to Receive it
timeFrame: 3 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai CDC
Study officials:
affiliation: University of Michigan
name: Abram L Wagner, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Huang Z, Ji M, Ren J, Sun X, Boulton ML, Zikmund-Fisher BJ, Wagner AL. Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine. Vaccine. 2022 Feb 7;40(6):897-903. doi: 10.1016/j.vaccine.2021.12.051. Epub 2022 Jan 4.